03-09-2026 22:56 via drugs.com

FDA Approves First-in-Class Drug for Polycythemia Vera

THURSDAY, Sept. 3, 2026-- The U.S. Food and Drug Administration has approved Mimrylo (rusfertide) as a new treatment for adults with polycythemia vera who have not achieved adequate control with existing therapies.Mimrylo mimics hepcidin, a...
Read more »

Pharmaceutical Industry news



Alcohol-Attributable Cancer Mortality Has Increased Significantly in the U.S.
Maintaining Physical Activity Tied to Better Quality of Life With Multiple Sclerosis
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
About 1 in 20 Hospitalized U.S. Adults With Firearm Injuries Develop Bacterial Infections
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage
Focal Therapy Use Remains Uncommon in Nonmetastatic Prostate Cancer
Causes, Outcomes of Traumatic Brain Injury Identified Worldwide
FDA Clears Blood Test for Alzheimer Disease
Time-Restricted Eating May Help Patients With Type 1 Diabetes
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women
ESC: Silent Atherosclerosis Present in 57.1 Percent of Adults Aged 18 to 70
ESC: Atorvastatin Lowers Cardiovascular Event Risk in Older Adults Without Clinical CVD
Updated Recommendations Address Medications to Prevent Migraine in Adults
Desktop versie